CD34 and neoplasm: Accordingly, we observed that the median percentage of CD34+/CD45dim/CD117+ cells negative for annexin V at baseline was significantly lower in patients with tumor response, as compared to those with stable or progressive disease (p = 0.005) (Figure 3B).